FDA Approves HIV Drug for Newborns Under Four Weeks

The FDA has expanded approval of dolutegravir oral suspension to treat HIV in newborns younger than 4 weeks old who weigh at least 2 kg. The decision was supported by a phase I study and pharmacokinetic modeling showing drug levels similar to those effective in adults. The safety profile was consistent with that seen in older patients.